NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis won new medical policy coverage for its PENFS therapy from a major national health insurer, extending patient access to approximately 18 million additional health plan members across multiple states. Its IB-Stim device is the only FDA-cleared therapy designed specifically for functional abdominal pain tied to IBS and functional dyspepsia in patients 8 and older, a population with no FDA-approved drug alternatives.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.